Don't Expect the New Antibiotic Plazomicin to Be Added to Formulary

September 2018

You'll see the new aminoglycoside, plazomicin (Zemdri, ZEM-dree), promoted for carbapenem-resistant Enterobacteriaceae (CRE).

It works like other aminoglycosides and has the same side effects...nephrotoxicity, ototoxicity, etc.

The difference is that plazomicin isn't as affected by aminoglycoside-modifying enzymes...the most common cause of aminoglycoside resistance to E. coli and other Enterobacteriaceae.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Antibiotics Don't Expect the New Antibiotic Plazomicin to Be Added to Formulary
Thrombolytics Weigh Thrombolytic Pros and Cons for Submassive Pulmonary Embolism
Bites & Stings Know the Difference Between CroFab and the New Snakebite Antivenom Anavip
Recalls The Valsartan Recall May Shake Up ARB Use at Your Hospital
Antibiotics Continue to Avoid Quinolones When Possible
New Drugs Stick With Clonidine When Using a Non-Opioid to Manage Acute Opioid Withdrawal
Diabetes Don't Jump to Newer Diabetes Meds for Renal Protection Yet
New Drugs Watch for Epidiolex, a New Rx Cannabinoid
Gout Consider Holding Febuxostat in Patients Admitted with CV Disease
New Drugs Hold the Low-Dose Vaginal Estrogen Imvexxy During Hospitalization

Don't Expect the New Antibiotic Plazomicin to Be Added to Formulary

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents